Imperial College London
Portrait Picture

Dr Frédéric B. Piel

Faculty of Medicine, School of Public Health

Senior Lecturer
 
 
 
//

Contact

 

f.piel

 
 
//

Location

 

1112Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Piel:2020:10.1016/S2352-3026(20)30143-5,
author = {Piel, F},
doi = {10.1016/S2352-3026(20)30143-5},
journal = {The Lancet Haematology},
pages = {e534--e540},
title = {Implementing newborn screening for sickle cell disease as part of immunization programmes in Nigeria: a feasibility study},
url = {http://dx.doi.org/10.1016/S2352-3026(20)30143-5},
volume = {7},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundSickle cell disease is highly prevalent in sub-Saharan Africa, where it accounts for substantial morbidity and mortality. Newborn screening is paramount for early diagnosis and enrolment of affected children into a comprehensive care programme. Up to now, this strategy has been greatly impaired in resource-poor countries, because screening methods are technologically and financially intensive; affordable, reliable, and accurate methods are needed. We aimed to test the feasibility of implementing a sickle cell disease screening programme using innovative point-of-care test devices into existing immunisation programmes in primary health-care settings.MethodsBuilding on a routine immunisation programme and using existing facilities and staff, we did a prospective feasibility study at five primary health-care centres within Gwagwalada Area Council, Abuja, Nigeria. We systematically screened for sickle cell disease consecutive newborn babies and infants younger than 9 months who presented to immunisation clinics at these five centres, using an ELISA-based point-of care test (HemoTypeSC). A subgroup of consecutive babies who presented to immunisation clinics at the primary health-care centres, whose mothers gave consent, were tested by the HemoTypeSC point-of-care test alongside a different immunoassay-based point-of-care test (SickleSCAN) and the gold standard test, high-performance liquid chromatography (HPLC).FindingsBetween July 14, 2017, and Sept 3, 2019, 3603 newborn babies and infants who presented for immunisation were screened for sickle cell disease at five primary health-care centres using the ELISA-based point-of-care test. We identified 51 (1%) children with sickle cell anaemia (HbSS), four (<1%) heterozygous for HbS and HbC (HbSC), 740 (21%) with sickle cell trait (HbAS), 34 (1%) heterozygous for HbA and HbC (HbAC), and 2774 (77%) with normal haemoglobin (HbAA). Of the 55 babies and infants with confirmed sickle cell disease, 41 (75%) were enrol
AU  - Piel,F
DO  - 10.1016/S2352-3026(20)30143-5
EP  - 540
PY  - 2020///
SN  - 2352-3026
SP  - 534
TI  - Implementing newborn screening for sickle cell disease as part of immunization programmes in Nigeria: a feasibility study
T2  - The Lancet Haematology
UR  - http://dx.doi.org/10.1016/S2352-3026(20)30143-5
UR  - https://www.sciencedirect.com/science/article/pii/S2352302620301435?via%3Dihub
UR  - http://hdl.handle.net/10044/1/79848
VL  - 7
ER  -
Download